A facile drug delivery system preparation through the interaction between drug and iron ion of transferrin
Source abstract
Abstract
Many anticancer drugs have the capability to form stable complex with metal ions. Based on such property, a simple method to combine these drugs with transferrin, through the interaction between drug and Fe ion of transferrin, to improve their anticancer activity, is proposed. To demonstrate this technique, the complex of photosensitive anticancer drug hypocrellin A and transferrin was prepared by such facile method. The results indicated that the complex of hypocrellin A and transferrin can stabilize in aqueous solution. In vitro studies have demonstrated the superior cancer cell uptake ability of hypocrellin A–transferrin complex to the free hypocrellin A. Significant damage to such drug-impregnated tumor cells was observed upon irradiation and the cancer cells killing ability of hypocrellin A–transferrin was stronger than the free hypocrellin A within a certain range of concentrations. The above results demonstrated the validity and potential of our proposed strategy to prepare the drug delivery system of this type of anti-cancer drugs and transferrin.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Protein Interaction Studies and Fluorescence Analysis · Hemoglobin structure and function
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Accardi L, Di Bonito P (2010) Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem 17(17):1730–175510.2174/092986710791111215 ↗
2. Anand S, Ortel BJ, Pereira SP, Hasan T, Maytin EV (2012) Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett 326(1):8–1610.1016/j.canlet.2012.07.026 ↗
3. Bareford LA, Swaan PW (2007) Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 59(8):748–75810.1016/j.addr.2007.06.008 ↗
4. Barreiro E, Casas JS, Couce MD, Sanchez A, Sanchez-Gonzalez A, Sordo J, Varela JM, Lopez EMV (2010) Dinuclear triphenylphosphinegold(I) sulfanylcarboxylates: synthesis, structure and cytotoxic activity against cancer cell lines. J Inorg Biochem 104(5):551–55910.1016/j.jinorgbio.2010.01.006 ↗
5. Bozec A, Fischel JL, Milano G (2006) Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol 18(4):330–33410.1097/01.cco.0000228737.78003.06 ↗
6. Cao J, Liu Y, Jia L, Zhou HM, Kong Y, Yang G, Jiang LP, Li QJ, Zhong LF (2007) Curcurnin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radical Biol Med 43(6):968–97510.1016/j.freeradbiomed.2007.06.006 ↗
7. Cavicchioli M, Massabni AC, Heinrich TA, Costa-Neto CM, Abrao EP, Fonseca BAL, Castellano EE, Corbi PP, Lustri WR, Leite CQF (2010) Pt(II) and Ag(I) complexes with acesulfame: crystal structure and a study of their antitumoral, antimicrobial and antiviral activities. J Inorg Biochem 104(5):533–54010.1016/j.jinorgbio.2010.01.004 ↗
8. Chen JN, Huang YW, Liu GS, Afrasiabi Z, Sinn E, Padhye S, Ma Y (2004) The cytotoxicity and mechanisms of 1,2-naphtoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Toxicol Appl Pharmacol 197(1):40–4810.1016/j.taap.2004.02.004 ↗
9. Ciardiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Inv Drugs 11(6):755–76810.1517/13543784.11.6.755 ↗
10. Dai N, Guo J, Teo YN, Kool ET (2011) Protease probes built from DNA: multispectral fluorescent DNA-peptide conjugates as caspase chemosensors. Angew Chem Int Ed 50(22):5105–510910.1002/anie.201007805 ↗
11. Das S, Bhattacharya A, Mandal PC, Rath MC, Mukherjee T (2002) One-electron reduction of 1,2-dihydroxy-9, 10-anthraquinone and some of its transition metal complexes in aqueous solution and in aqueous isopropanol-acetone-mixed solvent: a steady-state and pulse radiolysis study. Radiat Phys Chem 65(1):93–10010.1016/S0969-806X(01)00451-0 ↗
12. Das M, Mohanty C, Sahoo SK (2009) Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 6(3):285–30410.1517/17425240902780166 ↗
13. de Ilarduya CT, Duzgunes N (2000) Efficient gene transfer by transferrin lipoplexes in the presence of serum. Biochim Biophys Acta Biomembr 1463(2):333–34210.1016/S0005-2736(99)00225-4 ↗
14. Du XL, Zhang TI, Yuan L, Zhao YY, Li RC, Wang K, Yan SC, Zhang L, Sun HZ, Qian ZM (2002) Complexation of ytterbium to human transferrin and its uptake by K562 cells. Eur J Biochem 269(24):6082–609010.1046/j.1432-1033.2002.03326.x ↗
15. Du HY, Xiang JF, Zhang YZ, Tang YL (2007) A spectroscopic and molecular modeling of sinomenine binding to transferrin. Bioorg Med Chem Lett 17(6):1701–170410.1016/j.bmcl.2006.12.069 ↗
16. Du HY, Xiang JF, Zhang YZ, Tang YL, Xu GZ (2008) Binding of V–IV to human transferrin: Potential relevance to anticancer activity of vanadocene dichloride. J Inorg Biochem 102(1):146–14910.1016/j.jinorgbio.2007.07.030 ↗
17. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J (2012) Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target 20(10):813–83010.3109/1061186X.2012.716845 ↗
18. Katsogiannou M, Peng L, Catapano CV, Rocchi P (2011) Active-targeted nanotherapy strategies for prostate cancer. Curr Cancer Drug Targets 11(9):954–96510.2174/156800911797264770 ↗
19. Kim TH, Jo YG, Jiang HH, Lim SM, Youn YS, Lee S, Chen XY, Byun Y, Lee KC (2012) PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Controlled Release 162(2):422–42810.1016/j.jconrel.2012.07.021 ↗
20. Kostyuk VA, Potapovich AI, Vladykovskaya EN, Korkina LG, Afanas’ev IBA (2001) Influence of metal ions on flavonoid protection against asbestos-induced cell injury. Arch Biochem Biophys 385(1):129–13710.1006/abbi.2000.2118 ↗
21. Kratz F, Elsadek B (2012) Clinical impact of serum proteins on drug delivery. J Controlled Release 161(2):429–44510.1016/j.jconrel.2011.11.028 ↗
22. Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Controlled Release 161(2):175–18710.1016/j.jconrel.2011.09.063 ↗
23. Li HY, Qian ZM (2002) Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 22(3):225–25010.1002/med.10008 ↗
24. Li HY, Sun HZ, Qian ZM (2002) The role of the transferrin–transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci 23(5):206–20910.1016/S0165-6147(02)01989-2 ↗
25. Li SPY, Tang TSM, Yiu KSM, Lo KKW (2012) Cyclometalated iridium(III)-polyamine complexes with intense and long-lived multicolor phosphorescence: synthesis, crystal structure, photophysical behavior, cellular uptake, and transfection properties. Chem Eur J 18(42):13342–1335410.1002/chem.201200979 ↗
26. Liang XL, Li XD, Yue XL, Dai ZF (2011) Conjugation of porphyrin to nanohybrid cerasomes for photodynamic diagnosis and therapy of cancer. Angew Chem Int Ed 50(49):11622–1162710.1002/anie.201103557 ↗
27. Low PS, Henne WA, Doorneweerd DD (2008) Discovery and development of folic-acid-based receptor targeting for Imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41(1):120–12910.1021/ar7000815 ↗
28. Luo LZ, Jin HW, Huang HQ (2012) Transferrin–cisplatin specifically deliver cisplatin to HepG2 cells in vitro and enhance cisplatin cytotoxicity. J Proteomics 77:237–25010.1016/j.jprot.2012.08.023 ↗
29. Ma F et al (2011) Spectroscopic studies on the interaction of elsinochrome A with myoglobin. Spectrosc Spect Anal 31(6):1601–1605
30. Minko T, Dharap SS, Pakunlu RI, Wang Y (2004) Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 5(4):389–40610.2174/1389450043345443 ↗
31. Nakase I, Lai H, Singh NP, Sasaki T (2008) Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm 354(1–2):28–3310.1016/j.ijpharm.2007.09.003 ↗
32. Nishiyama N, Morimoto Y, Jang WD, Kataoka K (2009) Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. Adv Drug Deliv Rev 61(4):327–33810.1016/j.addr.2009.01.004 ↗
33. Ojima I (2008) Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxolds as warheads. Acc Chem Res 41(1):108–11910.1021/ar700093f ↗
34. Park SY, Baik HJ, Oh YT, Oh KT, Youn YS, Lee ES (2011) A smart polysaccharide/drug conjugate for photodynamic therapy. Angew Chem Int Ed 50(7):1644–164710.1002/anie.201006038 ↗
35. Paszko E, Ehrhardt C, Senge MO, Kelleher DP, Reynolds JV (2011) Nanodrug applications in photodynamic therapy. Photodiagn Photodyn Ther 8(1):14–2910.1016/j.pdpdt.2010.12.001 ↗
36. Patri AK, Kukowska-Latallo JF, Baker JR (2005) Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 57(15):2203–221410.1016/j.addr.2005.09.014 ↗
37. Qian ZM, Li HY, Sun HZ, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54(4):561–58710.1124/pr.54.4.561 ↗
38. Rajendiran V, Palaniandavar M, Periasamy VS, Akbarsha MA (2010) [Ru(phen)(2)(dppz)](2+) as an efficient optical probe for staining nuclear components. J Inorg Biochem 104(2):217–22010.1016/j.jinorgbio.2009.10.018 ↗
39. Rudnev AV, Foteeva LS, Kowol C, Berger R, Jakupec MA, Arion VB, Timerbaev AR, Keppler BK (2006) Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins. J Inorg Biochem 100(11):1819–182610.1016/j.jinorgbio.2006.07.003 ↗
40. Russell-Jones G, McTavish K, McEwan J, Rice J, Nowotnik D (2004) Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 98(10):1625–163310.1016/j.jinorgbio.2004.07.009 ↗
41. Shapira A, Livney YD, Broxterman HJ, Assaraf YG (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updates 14(3):150–16310.1016/j.drup.2011.01.003 ↗
42. Sterz K, Mollmann L, Jacobs A, Baumert D, Wiese M (2009) Activators of P-glycoprotein: structure-activity relationships and investigation of their mode of action. ChemMedChem 4(11):1897–191110.1002/cmdc.200900283 ↗
43. Subbaram S, DiPersio CM (2011) Integrin alpha 3 beta 1 as a breast cancer target. Expert Opin Ther Tar 15(10):1197–121010.1517/14728222.2011.609557 ↗
44. Tai WY, Mahato R, Cheng K (2010) The role of HER2 in cancer therapy and targeted drug delivery. J Controlled Release 146(3):264–27510.1016/j.jconrel.2010.04.009 ↗
45. Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y (2004) Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 277(1–2):39–6110.1016/j.ijpharm.2003.09.050 ↗
46. Tang W, Xu H, Kopelman R, Philbert MA (2005) Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms. Photochem Photobiol 81(2):242–24910.1562/2004-05-24-RA-176.1 ↗
47. Tang J, Yang C, Zhou L, Ma F, Liu SC, Wei SH, Zhou JH, Zhou YH (2012) Studies on the binding behavior of prodigiosin with bovine hemoglobin by multi-spectroscopic techniques. Spectrochim Acta, Part A 96:461–46710.1016/j.saa.2012.05.059 ↗
48. Wei GC, Yan MM, Dong RH, Wang D, Zhou XZ, Chen JF, Hao JC (2012) Covalent modification of reduced graphene oxide by means of diazonium chemistry and use as a drug-delivery system. Chem Eur J 18(46):14708–1471610.1002/chem.201200843 ↗
49. Widera A, Norouziyan F, Shen WC (2003) Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 55(11):1439–146610.1016/j.addr.2003.07.004 ↗
50. Yan F, Kopelman R (2003) The embedding of meta-tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties. Photochem Photobiol 78(6):587–59110.1562/0031-8655(2003)078<0587:TEOMIS>2.0.CO;2 ↗
51. Yang PH, Sun XS, Chiu JF, Sun HZ, He QY (2005) Transferrin-mediated gold nanoparticle cellular uptake. Bioconjugate Chem 16(3):494–49610.1021/bc049775d ↗
52. Yang C, Ma F, Tang J, Han LN, Wei SH, Zhou L, Zhou JH, Shen J, Wang F (2012) Synthesis of vanadyl–hypocrellin A complex and its photodynamic properties research. Bioorg Med Chem Lett 22(15):5003–500710.1016/j.bmcl.2012.06.025 ↗
53. Yong KT, Qian J, Roy I, Lee HH, Bergey EJ, Tramposch KM, He SL, Swihart MT, Maitra A, Prasad PN (2007) Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. Nano Lett 7(3):761–76510.1021/nl063031m ↗
54. Yu CL, Xu SJ, Chen S, Zhang MH, Shen T (2002) Investigation of photobleaching of hypocrellin B in non-polar organic solvent and in liposome suspension. J Photochem Photobiol, B 68(2–3):73–78
55. Zhao YY, Mandal R, Li XF (2005) Intact human holo-transferrin interaction with oxaliplatin. Rapid Commun Mass Spectrom 19(14):1956–196210.1002/rcm.2010 ↗
56. Zhou JH, Liu JH, Xia SQ, Wang XS, Zhang BW (2005) Effect of chelation to lanthanum ions on the photodynamic properties of hypocrellin A. J Phys Chem B 109(41):19529–1953510.1021/jp0522563 ↗
57. Zhou JH et al (2009) Spectroscopic studies on the interaction of hypocrellin A and hemoglobin. Spectrochim Acta, Part A 72(1):151–15510.1016/j.saa.2008.09.009 ↗
58. Zhou L, Liu JH, Ma F, Wei SH, Feng YY, Zhou JH, Yu BY, Shen J (2010a) Mitochondria-targeting photosensitizer-encapsulated amorphous nanocage as a bimodal reagent for drug delivery and biodiagnose in vitro. Biomed Microdev 12(4):655–66310.1007/s10544-010-9418-1 ↗
59. Zhou L, Liu JH, Zhang J, Wei SH, Feng YY, Zhou JH, Yu BY, Shen J (2010b) A new sol-gel silica nanovehicle preparation for photodynamic therapy in vitro. Int J Pharm 386(1–2):131–13710.1016/j.ijpharm.2009.11.010 ↗
60. Zhou L, Wang W, Tang J, Zhou JH, Jiang HJ, Shen J (2011) Graphene oxide noncovalent photosensitizer and its anticancer activity in vitro. Chem Eur J 17(43):12084–1209110.1002/chem.201003078 ↗
61. Zhou L, Jiang HJ, Wei SH, Ge XF, Zhou JH, Shen J (2012a) High-efficiency loading of hypocrellin B on graphene oxide for photodynamic therapy. Carbon 50(15):5594–560410.1016/j.carbon.2012.08.013 ↗
62. Zhou L, Wei SH, Ge XF, Zhou JH, Yu BY, Shen J (2012b) External heavy-atomic construction of photosensitizer nanoparticles for enhanced in vitro photodynamic therapy of cancer. J Phys Chem B 116(42):12744–1274910.1021/jp305137j ↗